ABSTRACT
Introduction: Treatment-free remission (TFR) in patients with chronic myeloid leukemia in chronic phase is considered a safe option if suitable molecular monitoring is available. However, the question arises as to which factors can contribute to the maintenance of TFR, and immunologic surveillance of the remaining leukemic cells is believed to be one of them. Argentina Stop Trial is an open-label, single-arm, multicenter trial assessing TFR after tyrosine kinase inhibitors interruption, that after more than 4 years showed a successful TFR rate of 63%. Methods: In this context, we set up an immunological study by flow cytometry in order to analyze specific NK cell subsets from peripheral blood patient samples both at the time of discontinuation as well as during the subsequent months. Results: At the time of discontinuation, patients show a mature NK cell phenotype, probably associated to TKI treatment. However, 3 months after discontinuation, significant changes in several NK cell receptors occurred. Patients with a higher proportion of CD56dim NK and PD-1+ NK cells showed better chances of survival. More interestingly, non-relapsing patients also presented a subpopulation of NK cells with features associated with the expansion after cytomegalovirus infection (expression of CD57+NKG2C+), and higher proportion of NKp30 and NKp46 natural cytotoxicity receptors, which resulted in greater degranulation and associated with better survival (p<0.0001). Discussion: This NK cell subset could have a protective role in patients who do not relapse, thus further characterization could be useful for patients in sustained deep molecular response.
Subject(s)
Leukemia, Myelogenous, Chronic, BCR-ABL Positive , Protein Kinase Inhibitors , Humans , Killer Cells, Natural , Protein Kinase Inhibitors/therapeutic use , Remission InductionABSTRACT
Treatment-free remission (TFR) in chronic myeloid leukemia (CML) is safe under adequate molecular monitoring, but questions remain regarding which factors may be considered predictive for TFR. Argentina Stop Trial (AST) is a multicenter TFR trial showing that 65% of patients sustain molecular remission, and the prior time in deep molecular response (DMR) was associated with successful TFR. Luminex technology was used to characterize cytokines in plasma samples. Using machine learning algorithms, MCP-1 and IL-6 were identified as novel biomarkers and MCP-1low/IL-6low patients showed eightfold higher risk of relapse. These findings support the feasibility of TFR for patients in DMR and MCP-1/IL-6 plasma levels are strong predictive biomarkers.
Subject(s)
Interleukin-6 , Leukemia, Myelogenous, Chronic, BCR-ABL Positive , Humans , Protein Kinase Inhibitors , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Biomarkers , Remission Induction , Treatment OutcomeABSTRACT
Se presenta la asociación de ruptura espontánea de bazo en dos pacientes con hemopatías malignas previamente diagnosticadas (leucemia mieloide crónica y leucemia linfoblástica aguda) y en un paciente con cuadro clínico inicial de trombocitemia esencial. Se destacan los aspectos clínicos, criterios diagnósticos, conductas terapéuticas y se revisa la literatura sobre esta grave patología(AU)
Subject(s)
Splenic Rupture , Leukemia , ThrombocytosisABSTRACT
Se presenta la asociación de ruptura espontánea de bazo en dos pacientes con hemopatías malignas previamente diagnosticadas (leucemia mieloide crónica y leucemia linfoblástica aguda) y en un paciente con cuadro clínico inicial de trombocitemia esencial. Se destacan los aspectos clínicos, criterios diagnósticos, conductas terapéuticas y se revisa la literatura sobre esta grave patología